641 related articles for article (PubMed ID: 15604213)
41. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer TJ; McIntosh CH; Pederson RA
Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
[TBL] [Abstract][Full Text] [Related]
42. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
43. Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice.
Gunnarsson PT; Winzell MS; Deacon CF; Larsen MO; Jelic K; Carr RD; Ahrén B
Endocrinology; 2006 Jul; 147(7):3173-80. PubMed ID: 16627575
[TBL] [Abstract][Full Text] [Related]
44. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs.
Deacon CF; Danielsen P; Klarskov L; Olesen M; Holst JJ
Diabetes; 2001 Jul; 50(7):1588-97. PubMed ID: 11423480
[TBL] [Abstract][Full Text] [Related]
45. Interaction of glucagon-like peptide-1(7-36) amide and gastric inhibitory polypeptide or cholecystokinin on insulin and glucagon secretion from the isolated perfused rat pancreas.
Suzuki S; Kawai K; Ohashi S; Watanabe Y; Yamashita K
Metabolism; 1992 Apr; 41(4):359-63. PubMed ID: 1556941
[TBL] [Abstract][Full Text] [Related]
46. The insulin response to gastric glucose is reduced in PAC1 and GRP receptor gene deleted mice.
Ahrén B
Nutr Metab Cardiovasc Dis; 2006 Mar; 16 Suppl 1():S17-21. PubMed ID: 16530124
[TBL] [Abstract][Full Text] [Related]
47. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility.
Miki T; Minami K; Shinozaki H; Matsumura K; Saraya A; Ikeda H; Yamada Y; Holst JJ; Seino S
Diabetes; 2005 Apr; 54(4):1056-63. PubMed ID: 15793244
[TBL] [Abstract][Full Text] [Related]
48. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
Marguet D; Baggio L; Kobayashi T; Bernard AM; Pierres M; Nielsen PF; Ribel U; Watanabe T; Drucker DJ; Wagtmann N
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6874-9. PubMed ID: 10823914
[TBL] [Abstract][Full Text] [Related]
49. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action.
Montrose-Rafizadeh C; Egan JM; Roth J
Endocrinology; 1994 Aug; 135(2):589-94. PubMed ID: 8033807
[TBL] [Abstract][Full Text] [Related]
50. Enhancing incretin action for the treatment of type 2 diabetes.
Drucker DJ
Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
[TBL] [Abstract][Full Text] [Related]
51. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion.
Jia X; Brown JC; Ma P; Pederson RA; McIntosh CH
Am J Physiol; 1995 Apr; 268(4 Pt 1):E645-51. PubMed ID: 7733263
[TBL] [Abstract][Full Text] [Related]
52. Evidence for neural contribution to islet effects of DPP-4 inhibition in mice.
Ahlkvist L; Omar B; Pacini G; Ahrén B
Eur J Pharmacol; 2016 Jun; 780():46-52. PubMed ID: 26997369
[TBL] [Abstract][Full Text] [Related]
53. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
54. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
55. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
56. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness.
Delmeire D; Flamez D; Moens K; Hinke SA; Van Schravendijk C; Pipeleers D; Schuit F
Biochem Pharmacol; 2004 Jul; 68(1):33-9. PubMed ID: 15183115
[TBL] [Abstract][Full Text] [Related]
57. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
58. Gut peptides in the treatment of diabetes mellitus.
Vahl TP; D'Alessio DA
Expert Opin Investig Drugs; 2004 Mar; 13(3):177-88. PubMed ID: 15013938
[TBL] [Abstract][Full Text] [Related]
59. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
van der Burg MP; Guicherit OR; Frölich M; Gooszen HG
Regul Pept; 1995 Dec; 60(1):61-7. PubMed ID: 8747785
[TBL] [Abstract][Full Text] [Related]
60. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
